The management of clostridium difficile infection

British Medical Bulletin

Volumn 91, Issue 1, 2009, Pages 87-110

  Williams, O Martin ^a   Spencer, Robert C ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Clostridium difficile; Risk factors; Treatment

Indexed keywords

COLESTYRAMINE; FUSIDIC ACID; LOPERAMIDE; METRONIDAZOLE; NITAZOXANIDE; ORITAVANCIN; RAMOPLANIN; RIFALAZIL; RIFAXIMIN; TIACUMICIN B; TOLEVAMER; VANCOMYCIN;

ALGORITHM; ANTIBIOTIC PROPHYLAXIS; BACTERIAL VIRULENCE; BIBLIOGRAPHIC DATABASE; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG INDICATION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; LABORATORY DIAGNOSIS; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CARRIER STATE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; RECURRENCE; RISK FACTORS;

EID: 69949128623     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldp021     Document Type: Review

References (148)

1. Spencer RC (1998) Clinical impact and associated, costs of Clostridium difficile-associated disease. J Antimieroh Chemother, 41 (Suppl C), 5-12.
2. Hall I, O'Toole E (1935) Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child, 49, 390-402
3. Lusk RH, Fekety FR Jr., Silva J Jr. et al. (1977) Gastrointestinal side effects of clindamycin and ampicillin therapy. J Infect Dis, 135 (Suppl), S111-S119.
4. Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL (1977) Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis, 136, 701-705.
5. Bartlett JG, Willey SH, Chang TW, Lowe B (1979) Cephalosporin-associated pseudomembranous colitis due to Clostridium difficile. JAMA, 242, 2683-2685.
6. Knoop FC, Owens M, Crocker IC (1993) Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev, 6, 251-265.
7. Birnbaum J, Bartlett JG, Gelber AC (2008) Clostridium difficile: an under-recognized cause of reactive arthritis? Clin Rheumatol, 27, 253-255.
8. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18, 247-263.
9. Borriello SP, Welch AR, Larson HE, Barclay F (1984) Diarrhoea and simultaneous excretion of Clostridium difficile cytotoxin and C perfringens enterotoxin. Lancet, 2, 1218. (Pubitemid 15217706)
10. Mattia AR, Doem GV, Clark J, Holden J, Wu L, Ferraro MJ (1993) Comparison of four methods in the diagnosis of Clostridium difficile disease. Eur J Clin Microbiol Infect Dis, 12, 882-886. (Pubitemid 24001435)
11. Johnson S, Kent SA, O'Leary KJ et al. (2001) Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 135, 434-438. (Pubitemid 32845868)
12. Planche T, Aghaizu A, Holliman R et al. (2008) Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis, 8, 777-784.
13. Miles BL, Siders JA, Allen SD (1988) Evaluation of a commercial latex test for Clostridium difficile for reactivity with C. difficile and cross-reactions with other bacteria. J Clin Microbiol, 26, 2452-2455.
14. Ticehurst JR, Aird DZ, Dam. LM, Borek. AP, Hargrove JT, Carroll KC (2006) Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol, 44, 1145-1149.
15. Fenner L, Widmer AF, Goy G, Rudin S, Frei R (2008) Rapid and reliable diagnostic algorithm, for detection of Clostridium difficile. J Clin Microbiol, 46, 328-330.
16. Wren MW, Sivapalan M, Kinson R, Shetty NR (2009) Laboratory diagnosis of Clostridium difficile infection. An evaluation of tests for faecal, toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostic laboratory. Br J Biomed Sci, 66, 1-5.
17. Steiner TS, Flores CA, Pizarro TT, Guerrant RL (1997) Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol, 4, 719-722.
18. Vaishnavi C, Bhasin D, Kochhar R, Singh K (2000) Clostridium difficile toxin and faecal lactoferrin assays in adult patients. Microbes Infect, 1, 1827-1830. (Pubitemid 32063535)
19. Borriello SP, Honour P (1981) Simplified procedure for the routine isolation of Clostridium difficile from faeces. J Clin Pathol, 34, 1124-1127.
20. Pepin J, Valiquette L, Alary ME et al. (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ, 171, 466-472.
21. Health Statistics Quarterly 30 Spring (2006) Report: Deaths involving Clostridium difficile: England and Wales 1999-2004. National Stat, 56-60.
22. Health Protection Agency CDR Weekly (2005) Outbreak of Clostridium difficile in a hospital in South East England. CDR Weekly, 15.
23. Smith A (2005) Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Euro Surveill, 10, E050630 2.
24. McDonald LC, Killgore GE, Thompson A et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med, 353, 2433-2441.
25. Joseph R, Demeyer D, Vanrenterghem D, van den Berg R, Kuijper E, Delmee M. (2005) First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro Surveill, 10, E051020 4.
26. Kuijper EJ, Coignard B, Tull P (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect, 12 (Suppl 6), 2-18. (Pubitemid 44362038)
27. Tachon M, Cattoen C, Blanckaert K et al. (2006) First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. Euro Surveill, 11, E060504 1.
28. Warny M, Pepin. J, Fang A et al. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, 366, 1079-1084.
29. Rafii F, Sutherland J, Cerniglia C (2008) Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag, 4, 1343-1357.
30. Gerding DN, Olson MM, Peterson LR et al. (1986) Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med, 146, 95-100.
31. Gerding DN (1989) Disease associated with Clostridium difficile infection. Ann Intern Med, 110, 255-257. (Pubitemid 19062152)
32. McFarland LV, Stamm WE (1986) Review of Clostridium difficile-associated diseases. Am J Infect Control, 14, 99-109.
33. Golledge CL, McKenzie T, Riley TV (1989) Extended spectrum cephalosporins and Clostridium difficile. J Antimicrob Chemother, 23, 929-931.
34. Wilcox MH, Freeman, J, Fawley W et al. (2004) Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother, 54, 168-172. (Pubitemid 39028985)
35. Owens RC Jr., Donskey CJ, Gaynes RP, Loo VG, Muto CA (2008) Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis, 46 (Suppl 1), S19-S31. (Pubitemid 351323662)
36. Johnson S, Samore MH, Farrow KA et al. (1999) Epidemics of diarrhea caused by a clindamycin-resistant strain, of Clostridium difficile in four hospitals. N Engl J Med, 341, 1645-1651.
37. Spencer RC (1998) The role of antimicrobial agents in, the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother, 41 (Suppl C), 21-27. (Pubitemid 28230296)
38. Yip C, Loeb M, Salama S, Moss L, Olde J (2001) Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol, 22, 572-575. (Pubitemid 33104885)
39. McCusker ME, Harris AD, Perencevich E, Roghmann MC (2003) Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis, 9, 730-733.
40. Loo VG, Poirier L, Miller MA et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high, morbidity and mortality. N Engl J Med, 353, 2442-2449. (Pubitemid 41770165)
41. Muto CA, Pokrywka M, Shutt K et al. (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol, 26, 273-280. (Pubitemid 40445086)
42. Pepin J, Saheb N, Coulombe MA et al. (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis, 41, 1254-1260. (Pubitemid 41532667)
43. Carignan A, Allard C, Pepin J, Cossette B, Nault V, Valiquette L (2008) Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis, 46, 1838-1843.
44. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ (2007) Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk, factors. Clin Infect Dis, 45, 1543-1549.
45. Currie BP, Lemos-Filho L (2004) Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycinresistant enterococci. Antimicrob Agents Chemother, 48, 4427-4429.
46. Pultz Nj, Stiefel U, Donskey CJ (2005) Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycin-resistant enterococci and extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother, 49, 3513-3536. (Pubitemid 41060606)
47. Leonard J, Marshall JK, Moayyedi P (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol, 102, 2047-2056, quiz 2057. (Pubitemid 47301504)
48. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K (2000) Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM, 93, 175-181. (Pubitemid 30128705)
49. Gurian L, Ward TT, Katon RM (1982) Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium, difficile: influence of gastrointestinal, secretions on Clostridium difficile infection. Gastroenterology, 83, 465-469.
50. Jump RL, Pultz MJ, Donskey CJ (2007) Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism, to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother, 51, 2883-2887.
51. Wilson KH, Sheagren JN, Freter R (1985) Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis, 151, 355-361.
52. Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med, 346, 334-339.
53. Eglow R, Pothoulakis C, Itzkowitz S et al. (1992) Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased, toxin A receptor. J Clin Invest, 90, 822-829.
54. Rolfe RD (1991) Binding kinetics of Clostridium difficile toxins A and B to intestinal brush border membranes from infant and adult hamsters. Infect Immun, 59, 1223-1230.
55. Bender BS, Bennett R, Laughon BE et al. (1986) Is Clostridium difficile endemic in chroniccare facilities? Lancet, 2, 11-13.
56. Thomas DR, Bennett RG, Laughon BE, Greenough WB 3rd, Bartlett JG (1990) Postantibiotic colonization with Clostridium difficile in nursing home patients. J Am Geriatr Soc, 38, 415-420.
57. Simor AE, Yake SL, Tsimidis K (1993) Infection, due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis, 17, 672-678.
58. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE (2002) Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol, 23, 696-703. (Pubitemid 35315995)
59. Riggs MM, Sethi AK, Zabarsky TF, Eckstein, EC, Jump RL, Donskey CJ (2007) Asymptomatic carriers are a potential, source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis, 45, 992-998.
60. Delmee M, Vandercam B, Avesani, V, Michaux JL (1987) Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol, 6, 623-627. (Pubitemid 18000963)
61. Kerr RB, McLaughlin DI, Sonnenberg LW (1990) Control of Clostridium difficile colitis outbreak, by treating asymptomatic carriers with metronidazole. Am J Infect Control, 18, 332-335.
62. Johnson, S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson, LR et al. (1992) Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin, or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med, 117, 297-302.
63. Bignardi GE (1998) Risk factors for Clostridium difficile infection. J Hosp Infect, 40, 1-15. (Pubitemid 28438966)
64. Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. ScandJ Gastroenterol, 32, 920-924.
65. Tedesco FJ (1976) Clindamycin-associated colitis. Review of the clinical, spectrum of 47 cases. Am J Dig Dis, 21, 26-32.
66. Tedesco FJ, Barton RW, Alpers DH (1974) Clindamycin-associated colitis. A prospective study. Ann Intern Med, 81, 429-433.
67. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I (2007) Outcomes of Clostridium difficile-associated disease treated, with metronidazole or vancomycin, before and after the emergence of NAP1/027. Am J Gastroenterol, 102, 2781-2788. (Pubitemid 350179349)
68. Louie TJ, Peppe J, Watt CK, Johnson D et al. (2006) Tolevamer, a novel, nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis, 43, 411-420. (Pubitemid 44157147)
69. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis, 45, 302-307.
70. Department of Health (2009) Clostridium difficile infection: how to deal with the problem. www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-093220 (accessed 11th February 2009).
71. Nelson, R (2007) Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev, CD004610.
72. Khan M, Hall W (1966) Staphylococcal enterocolitis-treatment with oral vancomycin. Ann Intern Med, 65, 1-8.
73. Pelaez T, Alcalá L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E (2002) Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother, 46, 1647-1650.
74. Bolton RP, Culshaw MA (1986) Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut, 27, 1169-1172.
75. Dion YM, Richards GK, Prentis JJ, Hinchey EJ (1980) The influence of oral versus parenteral preoperative metronidazole on sepsis following colon surgery. Ann Surg, 192, 221-226.
76. Teasley DG, Gerding DN, Olson MM et al. (1983) Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet, 2, 1043-1046.
77. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W (1996) Comparison, of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis, 22, 813-818. (Pubitemid 26255600)
78. Sethi, AK, Al-Nassir WN, Nerandzic MM, Donskey Cj (2009) Skin and environmental contamination with vancomycin-resistant Enterococci, in patients receiving oral, metronidazole or oral vancomycin, treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol, 30, 13-17.
79. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ (2008) Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci, during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother, 52, 2403-2406. (Pubitemid 351915669)
80. Musher DM, Aslam, S, Logan N et al. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis, 40, 1586-1590. (Pubitemid 40720807)
81. Gerding DN (2005) Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis, 40, 1598-1600. (Pubitemid 40720809)
82. Louie T, Gerson M, Johnson S, Poirier L, Weiss K, Peppe J et al. (2007) Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract 425a).
83. Apisamthanarak A, Khoury H, Reinus WR, Crippin JS, Mundy LM (2002) Severe Clostridium difficile colitis: the role of intracolonic vancomycin? Am J Med, 112, 328-329. (Pubitemid 34219453)
84. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG (1989) Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med, 86, 15-19. (Pubitemid 19039531)
85. McFarland LV, Elmer GW, Surawicz CM (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol, 97, 1769-1775.
86. Surawicz CM, McFarland LV, Greenberg RN et al. (2000) The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis, 31, 1012-1017.
87. Buggy BP, Fekety R, Silva J Jr. (1987) Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol, 9, 155-159. (Pubitemid 17046362)
88. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C (2006) Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis, 43, 547-552. (Pubitemid 44267111)
89. Noren T, Wullt M, Akerlund T, Back E, Odenholt I, Burman LG (2006) Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid, Antimicrob Agents Chemother, 50, 3028-3032. (Pubitemid 44396408)
90. Wullt M, Odenholt I (2004) A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother, 54, 211-216. (Pubitemid 39028992)
91. Koo HL, Koo DC, Musher DM, DuPont HL (2009) Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis, 48, 598-605.
92. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE (2004) Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum, 47, 1620-1626.
93. Lamontagne F, Labbe AC, Haeck O et al. (2007) Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an. epidemic caused by a hypervirulent strain. Ann Surg, 245, 267-272.
94. Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM (2008) Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg, 143, 150-154 (discussion 155).
95. Hall JF, Berger D (2008) Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg, 196, 384-388.
96. Bartlett JG (2006) Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med, 145, 758-764.
97. McFarland LV, Surawicz CM, Greenberg RN et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA, 271, 1913-1918.
98. Garey KW, Sethi S, Yadav Y, Dupont HL (2008) Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect, 70, 298-304.
99. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM (2007) Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm, 64, 2359-2363. (Pubitemid 350174708)
100. Pepin J, Routhier S, Gagnon S, Brazeau I (2006) Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis, 42, 758-764. (Pubitemid 43363928)
101. Tedesco FJ, Gordon D, Fortson WC (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. AmJ Gastroenterol, 80, 867-868. (Pubitemid 16233533)
102. Kyne L, Warny M, Qamar A, Kelly CP (2000) Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin. A. N Engl J Med, 342, 390-397. (Pubitemid 30084537)
103. Warny M, Vaerman JP, Avesani V, Delmee M (1994) Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun, 62, 384-389. (Pubitemid 24033753)
104. Kyne L, Warny M, Qamar A, Kelly CP (2001) Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet, 357, 189-193. (Pubitemid 32108091)
105. Hickson M, D'souza AL, Muthu N et al. (2007) Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ, 335, 80.
106. Dendukuri. N, Costa V, McGregor M, Brophy JM (2005) Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ, 173, 167-170. (Pubitemid 41032513)
107. Pillai A, Nelson R (2008) Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev, CD004611. (Pubitemid 351807675)
108. Besselink MG, van Santvoort HC, Buskens E et al. (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial, Lancet, 371, 651-659.
109. Cherifi S, Robberecht J, Miendje Y (2004) Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg, 59, 223-224. (Pubitemid 39489871)
110. Munoz P, Bouza E, Cuenca-Estrella M et al. (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis, 40, 1625-1634. (Pubitemid 40720813)
111. Enache-Angoulvant A, Hennequin C (2005) Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis, 41, 1559-1568. (Pubitemid 41691593)
112. Borriello SP, Barclay FE (1985) Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol, 19, 339-350.
113. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN (2002) Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis, 186, 1781-1789. (Pubitemid 35463511)
114. Merrigan MM, Sambol SP, Johnson S, Gerding DN (2003) Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis, 188, 1922-1927. (Pubitemid 38064879)
115. Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M. (1987) Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol, 6, 51-53.
116. Borody TJ, Warren. EF, Leis SM, Surace R, Ashman O, Siarakas S (2004) Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol, 38, 475-483.
117. Aas J, Gessert CE, Bakken JS (2003) Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis, 36, 580-585. (Pubitemid 36259562)
118. Fox LM, Saravolatz LD (2005) Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis, 40, 1173-1180.
119. McVay CS, Rolfe RD (2000) In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother, 44, 2254-2258.
120. Musher DM, Logan N, Hamill RJ et al. (2006) Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis, 43, 421-427. (Pubitemid 44157148)
121. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ (2007) Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother, 59, 705-710. (Pubitemid 47073405)
122. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF (2009) Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis, 48, e41-e46.
123. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC (2000) In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy, 46, 253-266. (Pubitemid 30428839)
124. Kokkotou E, Moss AC, Michos A et al. (2008) Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother, 52, 1121-1126. (Pubitemid 351358396)
125. Boero M, Berti E, Morgando A, Verme G (1990) Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximin vs. vancomycin. Microbiologia Medica, 5, 74-77.
126. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN (2007) Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis, 44, 846-848. (Pubitemid 46365312)
127. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN (2007) In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother, 51, 2716-2719. (Pubitemid 47206204)
128. O'Connor JR, Galang MA, Sambol SP et al. (2008) Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother, 52, 2813-2817.
129. Curry SR, Marsh JW, Shutt KA et al. (2009) High frequency of rifampin resistance identified in an, epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis, 48, 425-429.
130. Anton PM, O'Brien M, Kokkotou, E et al. (2004) Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother, 48, 3975-3979. (Pubitemid 39304630)
131. Biavasco F, Manso E, Varaldo PE (1991) In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother, 35, 195-197.
132. Pelaez T, Alcala L, Alonso R, Martin-Lopez A et al. (2005) In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother, 49, 1157-1159. (Pubitemid 40327739)
133. Freeman J, Baines SD, Jabes D, Wilcox MH (2005) Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection, J Antimicrob Chemother, 56, 717-725. (Pubitemid 41487774)
134. O'Connor R, Baines SD, Freeman J, Wilcox MH (2008) In vitro susceptibility of genotypically distinct and clonal. Clostridium difficile strains to oritavancin. J Antimicrob Chemother, 62, 762-765.
135. Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH (2008) Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother, 62, 1078-1085.
136. Lehoux D, Fadhil I, Gagne J, Bedaed I, Ostiguy V, Malouin M et al. (2008) Efficacy of oritavancin against Clostridium difficile (CD) infection in the hamster model of CD infection (CDI). In: 48th Interscience Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America, Washington (abstract B-067).
137. Ackermann G, Loffler B, Adler D, Rodloff AC (2004) In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother, 48, 2280-2282.
138. Shue YK, Sears PS, Shangle S et al. (2008) Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother, 52, 1391-1395.
139. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ (2009) Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection, Antimicrob Agents Chemother, 53, 223-228.
140. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M (2009) OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother, 53, 261-263.
141. Kurtz CB, Cannon EP, Brezzani A et al. (2001) GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother, 45, 2340-2347. (Pubitemid 32664476)
142. Braunlin W, Xu Q, Hook P et al. (2004) Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J, 87, 534-539. (Pubitemid 38880106)
143. Mattila E, Anttila VJ, Broas M et al. (2008) A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis, 40, 1-7.
144. Taylor CP, Tummala S, Molrine D et al, (2008) Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine, 26, 3404-3409.
145. Halsey J (2008) Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm, 65, 705-715. (Pubitemid 351555431)
146. Mayer MJ, Narbad A, Gasson MJ (2008) Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol, 190, 6734-6740.
147. Dubberke ER, Gerding DN, Classen D et al. (2008) Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol, 29 (Suppl 1), S81-S92.
148. Vonberg RP, Kuijper EJ, Wilcox MH et al. (2008) Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect, 14 (Suppl 5), 2-20.